These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 18414185)

  • 1. Urotensin II: a new pharmacologic target in the treatment of cardiovascular disease.
    Desai N; Sajjad J; Frishman WH
    Cardiol Rev; 2008; 16(3):142-53. PubMed ID: 18414185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System.
    Clozel M; Binkert C; Birker-Robaczewska M; Boukhadra C; Ding SS; Fischli W; Hess P; Mathys B; Morrison K; Müller C; Müller C; Nayler O; Qiu C; Rey M; Scherz MW; Velker J; Weller T; Xi JF; Ziltener P
    J Pharmacol Exp Ther; 2004 Oct; 311(1):204-12. PubMed ID: 15146030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptide Urotensin-II receptor agonists and antagonists: review and structure-activity relationships.
    Lescot E; Bureau R; Rault S
    Peptides; 2008 May; 29(5):680-90. PubMed ID: 18022732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three-dimensional model of the human urotensin-II receptor: docking of human urotensin-II and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model.
    Lescot E; Sopkova-de Oliveira Santos J; Colloc'h N; Rodrigo J; Milazzo-Segalas I; Bureau R; Rault S
    Proteins; 2008 Oct; 73(1):173-84. PubMed ID: 18409194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel insights into the role of urotensin II in cardiovascular disease.
    Pereira-Castro J; Brás-Silva C; Fontes-Sousa AP
    Drug Discov Today; 2019 Nov; 24(11):2170-2180. PubMed ID: 31430542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urotensin II and urotensin II-related peptide (URP) in cardiac ischemia-reperfusion injury.
    Prosser HC; Forster ME; Richards AM; Pemberton CJ
    Peptides; 2008 May; 29(5):770-7. PubMed ID: 17900760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of urotensin II and its receptor in health and disease.
    McDonald J; Batuwangala M; Lambert DG
    J Anesth; 2007; 21(3):378-89. PubMed ID: 17680191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiorenovascular effects of urotensin II and the relevance of the UT receptor.
    Tölle M; van der Giet M
    Peptides; 2008 May; 29(5):743-63. PubMed ID: 17935830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urotensin II: a vascular mediator in health and disease.
    Kemp W; Roberts S; Krum H
    Curr Vasc Pharmacol; 2005 Apr; 3(2):159-68. PubMed ID: 15853635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urotensin II receptor and acetylcholine release from mouse cervical spinal cord nerve terminals.
    Bruzzone F; Cervetto C; Mazzotta MC; Bianchini P; Ronzitti E; Leprince J; Diaspro A; Maura G; Vallarino M; Vaudry H; Marcoli M
    Neuroscience; 2010 Sep; 170(1):67-77. PubMed ID: 20620192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urotensin-II as a novel therapeutic target in the clinical management of cardiorenal disease.
    Gilbert RE; Douglas SA; Krum H
    Curr Opin Investig Drugs; 2004 Mar; 5(3):276-82. PubMed ID: 15083593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urotensin-II and UII-receptor expression and function in the rat adrenal cortex.
    Albertin G; Casale V; Ziolkowska A; Spinazzi R; Malendowicz LK; Rossi GP; Nussdorfer GG
    Int J Mol Med; 2006 Jun; 17(6):1111-5. PubMed ID: 16685423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A vasoactive peptide: urotensin II].
    Liu GQ; Zeng ZP
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Aug; 27(4):525-8. PubMed ID: 16178453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non peptidic urotensin II antagonists: perspectives for a new class of drugs.
    Cosenzi A
    Cardiovasc Hematol Agents Med Chem; 2008 Apr; 6(2):80-91. PubMed ID: 18473773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urotensin II: its function in health and its role in disease.
    Ong KL; Lam KS; Cheung BM
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):65-75. PubMed ID: 15883758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats.
    Trebicka J; Leifeld L; Hennenberg M; Biecker E; Eckhardt A; Fischer N; Pröbsting AS; Clemens C; Lammert F; Sauerbruch T; Heller J
    Hepatology; 2008 Apr; 47(4):1264-76. PubMed ID: 18318439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of therapeutic agents related to urotensin II].
    Mori M
    Nihon Rinsho; 2004 Sep; 62 Suppl 9():741-4. PubMed ID: 15506486
    [No Abstract]   [Full Text] [Related]  

  • 18. Urotensin II: a cardiovascular and renal update.
    Zoccali C; Mallamaci F
    Curr Opin Nephrol Hypertens; 2008 Mar; 17(2):199-204. PubMed ID: 18277155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urantide conformation and interaction with the urotensin-II receptor.
    Brancaccio D; Limatola A; Campiglia P; Gomez-Monterrey I; Novellino E; Grieco P; Carotenuto A
    Arch Pharm (Weinheim); 2014 Mar; 347(3):185-92. PubMed ID: 24357333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of blockade of the urotensin II system in systemic hypertension.
    Krum H; Kemp W
    Curr Hypertens Rep; 2007 Mar; 9(1):53-8. PubMed ID: 17362672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.